Celsion Corporation
Biotechnology, 997 Lenox Dr, Lawrence Township, New Jersey, 08648, United States, 11-50 Employees
Phone Number: 60********
Who is CELSION CORPORATION
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated im...
Read More
-
Headquarters: 997 Lenox Dr, Lawrence Township, New Jersey, 08648, United States
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 541720 |
Show More
Does something look wrong? Fix it. | View contact records from CELSION CORPORATION
Celsion Corporation Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Celsion Corporation
Answer: Celsion Corporation's headquarters are located at 997 Lenox Dr, Lawrence Township, New Jersey, 08648, United States
Answer: Celsion Corporation's phone number is 60********
Answer: Celsion Corporation's official website is https://celsion.com
Answer: Celsion Corporation's revenue is $10 Million to $25 Million
Answer: Celsion Corporation's SIC: 2834
Answer: Celsion Corporation's NAICS: 541720
Answer: Celsion Corporation has 11-50 employees
Answer: Celsion Corporation is in Biotechnology
Answer: Celsion Corporation contact info: Phone number: 60******** Website: https://celsion.com
Answer: Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsions mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month